Failed Alzheimer's trial leaves families and patients heartbroken. Medical community reels
March 23, 2019 at 12:24 PM EDT
Biogen and Eisai lost billions of dollars in market value after halting two late-stage trials of a promising experimental Alzheimer's drug.